This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Allison, A C Search for Related Content PubMed PubMed Citation Articles by Allison, A C Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AZATHIOPRINE NITRIC OXIDE Social Bookmarking                         What's this?

Mechanisms of action of mycophenolate mofetil

SurroMed, Inc., Menlo Park, CA, USA, aallison{at}surromed.com

Mycophenolate mofetil (MMF, CellCept®) is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-50-monophosphate dehydrogenase. MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation. MPA also inhibits the glycosylation and expression of adhesion molecules, and the recruitment of lymphocytes and monocytes into sites of inflammation. MPA depletes tetrahydrobiopterin and decreases the production of nitric oxide by inducible NO synthase without affecting the activity of constitutive NO synthases. Activated macrophages produce NO and superoxide, which combine to generate tissue-damaging peroxynitrite. By these two mechanisms MMF exerts anti-inflammatory activity. Unlike calcineurin inhibitors, MMF is not nephrotoxic and does not induce the production of TGFb, which is fibrogenic. MMF does not increase blood pressure, cholesterol levels or triglyceride levels in recipients. MMF reduces acute and chronic rejection in allograft recipients and is efficacious in some nephropathies. Evidence is accumulating that MMF may have clinical utility in some autoimmune disorders.

Key Words: antibodies • arthropathy • immunosuppressive • lymphocytes • monocytes • nephropathy

Lupus, Vol. 14, No. 3 suppl, s2-s8 (2005)
DOI: 10.1191/0961203305lu2109oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]

				X.-X. Sun, M.-S. Dai, and H. Lu Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11 J. Biol. Chem., May 2, 2008; 283(18): 12387 - 12392. [Abstract] [Full Text] [PDF]

				A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]

				Y. Bravo, Y. Quiroz, A. Ferrebuz, N. D. Vaziri, and B. Rodriguez-Iturbe Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension Am J Physiol Renal Physiol, August 1, 2007; 293(2): F616 - F623. [Abstract] [Full Text] [PDF]

				P. M Stassen, J. W. Cohen Tervaert, and C. A Stegeman Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide Ann Rheum Dis, June 1, 2007; 66(6): 798 - 802. [Abstract] [Full Text] [PDF]

				P. M. Stassen, C. G. M. Kallenberg, and C. A. Stegeman Use of mycophenolic acid in non-transplant renal diseases Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1013 - 1019. [Full Text] [PDF]

				S. I. Nihtyanova, G. M. Brough, C. M. Black, and C. P. Denton Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis Rheumatology, March 1, 2007; 46(3): 442 - 445. [Abstract] [Full Text] [PDF]

				S. I. van Leuven, J. J.P. Kastelein, A. C. Allison, M. R. Hayden, and E. S.G. Stroes Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles? Cardiovasc Res, February 1, 2006; 69(2): 341 - 347. [Abstract] [Full Text] [PDF]

				P Vermersch, T Stojkovic, and J de Seze Mycophenolate mofetil and neurological diseases Lupus, March 1, 2005; 14(3_suppl): s42 - s45. [Abstract] [PDF]

				P. Vermersch, T. Stojkovic, and J. de Seze Mycophenolate mofetil and neurological diseases Lupus, January 1, 2005; 14(1_suppl): s42 - s45. [Abstract] [PDF]